Syed A Ahmad1, Mai Duong2, Davendra P S Sohal1, Namita S Gandhi3, Muhammad Shaalan Beg4, Andrea Wang-Gillam5, James L Wade6, Elena Gabriela Chiorean7, Katherine A Guthrie2, Andrew M Lowy8, Philip A Philip9, Howard S Hochster10. 1. University of Cincinnati, Cincinnati, Ohio. 2. SWOG Statistical and Data Management Center, Seattle, Washington. 3. Cleveland Clinic, Cleveland, Ohio. 4. UT Southwestern Medical Center, Dallas, Texas. 5. Washington University Siteman Cancer Center, St. Louis, Missouri. 6. Heartland NCORP/Cancer Care Specialists of Illinois, Decatur, Illinois. 7. University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington. 8. University of California, San Diego, La Jolla, California. 9. Wayne State University/Karmanos Cancer Institute, Detroit, Michigan. 10. Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Abstract
OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2). Measured parameters included resection rate, margin positivity, pathologic response, and toxicity. RESULTS: Between 2015 and 2018, 147 patients were randomized. Of these, 44 (30%) were deemed ineligible (43 by central review). Of the 103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7). Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy. The grade 3-5 postoperative complication rate was 16%. Of the 73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy. This study represents the first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA. CONCLUSIONS: We have demonstrated: (1) Based on the high percentage of enrolled, but ineligible patients, it is clear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resection without prohibitive perioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficult; (4) Major pathologic response rate of 33% is encouraging.
OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel (Arm 2). Measured parameters included resection rate, margin positivity, pathologic response, and toxicity. RESULTS: Between 2015 and 2018, 147 patients were randomized. Of these, 44 (30%) were deemed ineligible (43 by central review). Of the 103 eligible patients, 77 (76%) completed preoperative therapy and underwent surgery; reasons patients did not undergo surgery included toxicity related to preoperative therapy (n = 9), progression (n = 9), or other (n = 7). Of the 77, 73 (95%) underwent successful resection; 21 (29%) required vascular reconstruction, 62 (85%) had negative (R0) margins, and 24 (33%) had a complete or major pathologic response to therapy. The grade 3-5 postoperative complication rate was 16%. Of the 73 patients completing surgery, 57 (78%) started and 46 (63%) completed postoperative therapy. This study represents the first prospective trial evaluating modern systemic therapy delivered in a neoadjuvant/perioperative format for resectable PDA. CONCLUSIONS: We have demonstrated: (1) Based on the high percentage of enrolled, but ineligible patients, it is clear that adherence to strict definitions of resectable PDA is challenging; (2) Patients can tolerate modern systemic therapy and undergo successful surgical resection without prohibitive perioperative complications; (3) Completion of adjuvant therapy in the perioperative format is difficult; (4) Major pathologic response rate of 33% is encouraging.
Authors: N Volkan Adsay; Olca Basturk; Burcu Saka; Pelin Bagci; Denizhan Ozdemir; Serdar Balci; Juan M Sarmiento; David A Kooby; Charles Staley; Shishir K Maithel; Rhonda Everett; Jeanette D Cheng; Duangpeng Thirabanjasak; Donald W Weaver Journal: Am J Surg Pathol Date: 2014-04 Impact factor: 6.394
Authors: Matthew H G Katz; Robert Marsh; Joseph M Herman; Qian Shi; Eric Collison; Alan P Venook; Hedy L Kindler; Steven R Alberts; Philip Philip; Andrew M Lowy; Peter W T Pisters; Mitchell C Posner; Jordan D Berlin; Syed A Ahmad Journal: Ann Surg Oncol Date: 2013-02-23 Impact factor: 5.344
Authors: Eva Versteijne; Mustafa Suker; Karin Groothuis; Janine M Akkermans-Vogelaar; Marc G Besselink; Bert A Bonsing; Jeroen Buijsen; Olivier R Busch; Geert-Jan M Creemers; Ronald M van Dam; Ferry A L M Eskens; Sebastiaan Festen; Jan Willem B de Groot; Bas Groot Koerkamp; Ignace H de Hingh; Marjolein Y V Homs; Jeanin E van Hooft; Emile D Kerver; Saskia A C Luelmo; Karen J Neelis; Joost Nuyttens; Gabriel M R M Paardekooper; Gijs A Patijn; Maurice J C van der Sangen; Judith de Vos-Geelen; Johanna W Wilmink; Aeilko H Zwinderman; Cornelis J Punt; Casper H van Eijck; Geertjan van Tienhoven Journal: J Clin Oncol Date: 2020-02-27 Impact factor: 44.544
Authors: Janet E Murphy; Jennifer Y Wo; David P Ryan; Wenqing Jiang; Beow Y Yeap; Lorraine C Drapek; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Jason E Faris; Andrew X Zhu; Lipika Goyal; Keith D Lillemoe; Thomas F DeLaney; Carlos Fernández-Del Castillo; Cristina R Ferrone; Theodore S Hong Journal: JAMA Oncol Date: 2018-07-01 Impact factor: 31.777
Authors: Mashaal Dhir; Mazen S Zenati; Ahmad Hamad; Aatur D Singhi; Nathan Bahary; Melissa E Hogg; Herbert J Zeh; Amer H Zureikat Journal: Ann Surg Oncol Date: 2018-05-14 Impact factor: 5.344
Authors: Ryan P Merkow; Karl Y Bilimoria; James S Tomlinson; Jennifer L Paruch; Jason B Fleming; Mark S Talamonti; Clifford Y Ko; David J Bentrem Journal: Ann Surg Date: 2014-08 Impact factor: 12.969
Authors: Matthew H G Katz; Qian Shi; Syed A Ahmad; Joseph M Herman; Robert de W Marsh; Eric Collisson; Lawrence Schwartz; Wendy Frankel; Robert Martin; William Conway; Mark Truty; Hedy Kindler; Andrew M Lowy; Tanios Bekaii-Saab; Philip Philip; Mark Talamonti; Dana Cardin; Noelle LoConte; Perry Shen; John P Hoffman; Alan P Venook Journal: JAMA Surg Date: 2016-08-17 Impact factor: 14.766
Authors: Matthew H G Katz; Fang-Shu Ou; Joseph M Herman; Syed A Ahmad; Brian Wolpin; Robert Marsh; Spencer Behr; Qian Shi; Michael Chuong; Lawrence H Schwartz; Wendy Frankel; Eric Collisson; Eugene J Koay; JoLeen M Hubbard; James L Leenstra; Jeffrey Meyerhardt; Eileen O'Reilly Journal: BMC Cancer Date: 2017-07-27 Impact factor: 4.430
Authors: Brandon C Chapman; Ana Gleisner; Devin Rigg; Wells Messersmith; Alessandro Paniccia; Cheryl Meguid; Csaba Gajdos; Martin D McCarter; Richard D Schulick; Barish H Edil Journal: JOP Date: 2018-03-30
Authors: Paul R Burchard; Alexander C Chacon; Alexa Melucci; Anthony S Casabianca; Subir Goyal; Jeffrey M Switchenko; Shishir K Maithel; David A Kooby; Darren R Carpizo; Mihir M Shah Journal: J Surg Oncol Date: 2022-01-07 Impact factor: 3.454
Authors: Hadass Rom; Shlomit Tamir; Jeroen L A Van Vugt; Yael Berger; Gali Perl; Sara Morgenstern; Ana Tovar; Baruch Brenner; Daniel Benchimol; Hanoch Kashtan; Eran Sadot Journal: Ann Surg Oncol Date: 2021-10-30 Impact factor: 5.344
Authors: Brett L Ecker; Colin M Court; Quisette P Janssen; Alice J Tao; Michael I D'Angelica; Jeffrey A Drebin; Mithat Gonen; Eileen M O'Reilly; William R Jarnagin; Alice C Wei Journal: J Am Coll Surg Date: 2022-04-05 Impact factor: 6.532
Authors: Ulrich Ronellenfitsch; Christoph W Michalski; Patrick Michl; Sebastian Krug; Joerg Ukkat; Joerg Kleeff Journal: Front Med (Lausanne) Date: 2021-05-24